At a glance

At a glance
CSR report
Consolidated Key Figures

(thousands of €, if not stated otherwise)

Third quarter of 2021

Third quarter of 2020

Nine months ended 30 September
2021

Nine months ended 30 September
2020

Year ended 31 December 2020

Income statement(*)

 

 

 

 

 

Product net sales

5,691

-

6,147

-

-

Collaboration revenues

58,503

127,519

311,711

321,923

478,053

Cost of sales

(529)

-

(660)

-

-

R&D expenditure

(109,196)

(129,298)

(378,022)

(392,199)

(523,667)

S, G&A expenses

(45,448)

(43,716)

(151,267)

(132,412)

(185,225)

Other operating income

12,781

12,201

36,345

35,003

52,207

Operating loss

(78,199)

(33,294)

(175,747)

(167,685)

(178,632)

Net financial results

13,743

(49,211)

33,659

(83,355)

(131,143)

Taxes

(157)

(14)

316

(723)

(1,226)

Net loss from continuing operations

(64,613)

(82,519)

(141,772)

(251,763)

(311,001)

Net profit from discontinued operations, net of tax

-

614

22,191

4,215

5,565

Net loss

(64,613)

(81,905)

(119,581)

(247,548)

(305,436)

 

 

 

 

 

 

Balance sheet

 

 

 

 

 

Cash and cash equivalents

2,834,378

2,087,797

2,834,378

2,087,797

2,135,187

Current financial investments

2,039,787

3,220,805

2,039,787

3,220,805

3,026,278

R&D incentives receivables

149,271

122,878

149,271

122,878

135,728

Assets

5,331,987

5,721,086

5,331,987

5,721,086

5,717,731

Shareholders' equity

2,617,383

2,712,082

2,617,383

2,712,082

2,670,355

Deferred income

2,520,652

2,789,183

2,520,652

2,789,183

2,809,133

Other liabilities

193,952

219,821

193,952

219,821

238,242

 

 

 

 

 

 

Cash flow

 

 

 

 

 

Operational cash burn(**)

(153,546)

(202,784)

(376,743)

(433,270)

(517,404)

Cash flow used in operating activities

(136,925)

(180,340)

(340,056)

(390,169)

(427,336)

Cash flow generated from/used in (-) investing activities

311,138

(81,084)

993,191

631,720

757,288

Cash flow generated from/used in (-) financing activities

(964)

353

(2,438)

20,599

22,040

Increase/decrease (-) in cash and cash equivalents

173,249

(261,073)

650,697

262,149

351,994

Effect of currency exchange rate fluctuation on cash and cash equivalents

18,489

(35,351)

40,610

(35,968)

(70,539)

Cash and cash equivalents at end of the period

2,834,378

2,087,797

2,834,378

2,087,797

2,143,071

 

 

 

 

 

 

Cash and cash equivalents from continuing operations

2,834,378

2,087,797

2,834,378

2,087,797

2,135,187

Cash and cash equivalents classified as assets held for sale

-

-

-

-

7,884

Current financial investments at the end of the period

2,039,787

3,220,805

2,039,787

3,220,805

3,026,278

Total current financial investments and cash and cash equivalents at the end of the period

4,874,165

5,308,602

4,874,165

5,308,602

5,169,349

 

 

 

 

 

 

Financial ratios

 

 

 

 

 

Number of shares issued at the end of the period

65,530,121

65,340,842

65,530,121

65,340,842

65,411,767

Basic and diluted loss per share (in €)

(0.99)

(1.25)

(1.83)

(3.81)

(4.69)

Share price at the end of the period (in €)

45.16

121.20

45.16

121.20

80.48

Total group employees at the end of the period (number)(***)

1,319

1,407

1,319

1,407

1,489

(*)

The comparatives of 30 September 2020 and the third quarter of 2020 have been restated to consider the impact of classifying the Fidelta business as discontinued operations in 2020.

(**)

We refer to the note on our cash position of our condensed consolidated interim financial statements for an explanation and reconciliation of this alternative performance measure.

(***)

The number of employees on 31 December 2020 and on 30 September 2020 included respectively 185 and 174 employees of Fidelta, which has been sold to Selvita on 4 January 2021.

Employees per site as of 30 September 2021

(total: 1,319 employees)

Employees per site as of 30 September 2021 (map)